Bergstresser P R, Schreiber S H, Weinstein G D
Arch Dermatol. 1976 Jul;112(7):977-81.
A questionnaire that was mailed to 510 randomly selected dermatologists in the United States surveyed their use of three systemic chemotherapeutic agents for the treatment of psoriasis during the two-year period of 1973 to 1974. Methotrexate was used by 52% of the surveyed dermatologists, while hydroxyurea and azaribine were used by 10% and 2%, respectively. Seventy-five percent of the dermatologists who used methotrexate treated ten or fewer psoriatic patients with this drug. Multiple dose therapy with methotrexate divided over a period of 36 hours each week was the preferred schedule of 66% of the dermatologists. Liver biopsy specimens and creatinine clearance tests were obtained for only 17% and 35% of patients, respectively, prior to initiating methotrexate therapy. The estimated number of dermatologist-treated psoriatics nationwide receiving methotrexate is 25,000.
一份调查问卷被邮寄给了美国随机挑选的510名皮肤科医生，调查他们在1973年至1974年这两年期间使用三种全身化疗药物治疗银屑病的情况。52%的受访皮肤科医生使用甲氨蝶呤，而羟基脲和阿扎立宾的使用率分别为10%和2%。使用甲氨蝶呤的皮肤科医生中有75%用这种药物治疗的银屑病患者为10名或更少。每周分36小时进行多剂量甲氨蝶呤治疗是66%的皮肤科医生首选的治疗方案。在开始甲氨蝶呤治疗之前，仅分别有17%的患者接受了肝活检标本检查，35%的患者进行了肌酐清除率测试。据估计，全国接受甲氨蝶呤治疗的由皮肤科医生诊治的银屑病患者有25000名。
